The controversial BIOSECURE Act is set to regain momentum in the U.S. House of Representatives during the week of September 9. The bill, introduced in January, aims to halt federal contracts with specific Chinese biotech companies, including WuXi AppTec and WuXi Biologics, due to concerns over national security and alleged ties to China’s military and intelligence agencies. Despite repeated denials from these firms, the legislation has garnered bipartisan support and passed out of the House Oversight Committee in May.
The House plans to consider the bill under the "suspension of the rules" process, which allows for quicker approval of less controversial measures. However, its future in the Senate remains uncertain, as standalone votes are rare. Many believe that the BIOSECURE Act is most likely to be integrated into the National Defense Authorization Act (NDAA), which sets the Defense Department’s budget. An earlier attempt to attach the bill to the NDAA in June failed to progress.
If enacted, the bill would require U.S. drugmakers to sever ties with the named Chinese biotech firms by 2032 to retain their standing in Medicare and Medicaid programs. Industry experts have expressed concern over the challenges U.S. companies would face in disentangling from long-standing partnerships with Chinese contract manufacturers and research organizations. A recent L.E.K. Consulting survey also highlighted a growing hesitation among U.S.-based life sciences companies to collaborate with Chinese firms due to the reputational damage already inflicted by the bill.
Click here to read the original news story.